Hydroxichloroquine for COVID-19 infection: Do we have a final word after one year?
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 34750033.
- Also identified by DOI 10.1016/j.ejim.2021.10.026 and PMC identifier PMC7760047.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The results presently available from randomised clinical trials and their meta-analysis indicate that Hydroxychloroquine is not associated in COVID-19 patients with either decreased mortality or clinical worsening. Thus, the use of Hydroxychloroquine in COVID-19 patients cannot at present be encouraged. However, the hypothesis that Hydroxychloroquine might have a beneficial role in subgroups of patients at low risk and/or when used at low dosage (≤ 400 mg/day) deserves to be tested in large, well designed randomised clinical trials.